TY - JOUR
T1 - Neuroendocrine and Rare Tumor Advances
T2 - A New and Promising TRAIL Emerges
AU - Owen, Dwight H.
AU - Trikalinos, Nikolaos A.
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research
PY - 2022/5/1
Y1 - 2022/5/1
N2 - ONC201 is an oral selective antagonist of the dopamine D2 receptor and direct activator of caseinolytic protease P. In a phase II study, ONC021 was shown to be well tolerated with notable efficacy in patients with the rare neuroendocrine neoplasms pheochromocytomas-paragangliomas, although biomarkers for activity remain to be elucidated.
AB - ONC201 is an oral selective antagonist of the dopamine D2 receptor and direct activator of caseinolytic protease P. In a phase II study, ONC021 was shown to be well tolerated with notable efficacy in patients with the rare neuroendocrine neoplasms pheochromocytomas-paragangliomas, although biomarkers for activity remain to be elucidated.
UR - http://www.scopus.com/inward/record.url?scp=85129781781&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-0120
DO - 10.1158/1078-0432.CCR-22-0120
M3 - Article
C2 - 35491654
AN - SCOPUS:85129781781
SN - 1078-0432
VL - 28
SP - 1748
EP - 1750
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 9
ER -